Mucormycosis is termed as an angio-invasive fungal infection, connected with high morbidity and mortality. Analteration in the epidemiology of mucormycosis has been discovered in recent years with the rise in frequency,newfound causative agents and susceptible population. The rise has been perceived globally, but it is very advancedin the Asian continent. Though diabetes mellitus surpass all other risk factors in Asia. Posttuberculosis and chronicrenal failure have appeared as a new risk groups. The rhino cerebral mucormycosis is most usually seen in patientswith diabetes mellitus. Although considered to be an infrequent infection, mucormycosis (zygomycosis) hasemerged as the second most common invasive mould infection. Despite the advent of newer fungicidal agents,mortality rate of mucormycosis resides exceedingly higher. Successful direction of mucormycosis requires earlyidentification, reversal of underlying predisposing risk number, surgical debridement and prompt administration ofactive antifungal agents. However, mucormycosis is not always amenable to cure. There are challenging obstaclesthat lead to exertion in management of Amphotericin B. These include unique host-based risk factors formucormycosis, the fungus’ resistance to innate hostdefences and distinctive features of its immunopathogenesis,such as extensive angioinvasion, increased virulence and use of chelators by the fungus as siderophores.

Keywords:Mucormycosis, Types of Mucormycosis, Mucormycosis in COVID-19

Abbreviations: ROCM :Rhino cerebral Mucormycosis, HIV: Human Immuno Deficiency virus , AIDS: Acquired Immuno Deficiency Syndrome